Aprea Therapeutics Inc. (APRE) is a biopharmaceutical company with an intense focus on developing and commercializing novel cancer therapies that show potential to redefine the standards of care. The firm, which was established in 2006, is located in Boston, Massachusetts and Stockholm, Sweden. It is incorporated in the state of Delaware in the United States and is publicly traded on the NASDAQ stock exchange under the ticker symbol 'APRE.'
Aprea Therapeutics Inc. primarily targets the p53 tumor suppressor protein, the gene for which is deleted or mutated in about half of all human cancers. It developed the concept of small molecules called PRIMA Met Inhibitor that targets p53 and effectively enhance its ability in restoring the cell cycle arrest and trigger cell death in cancer cells. The main research compound currently in development is EP300-initiated p53 reactivation compounds. The most advanced of these innovations is aprinocarsen (APR-246), now in clinical phase 3 trial for treatment of myelodysplastic syndromes (MDS), a group of rare blood disorders. This constitutes a paradigm shift in cancer treatment showing substantial promise, and APRE is striving to develop it for a broad range of human cancers.
Aprea Therapeutics also has a substantive drug pipeline of several promising and innovative compounds in different stages of clinical development for the treatment of various forms of cancer. These achievements highlight the company's commitment to research and development, and its drive for innovation in the field of cancer therapy.
The firm's leadership comprises a team of passionate scientists, investors, and businessmen with extensive experience in biotechnology and life sciences. They partner with world-class investors, research institutions, and scientists, with the shared goal of transforming the landscape of cancer therapy.
Despite being a relatively young company, Aprea Therapeutics Inc has shown strong growth potential and dedication to its mission. The future advancements from this company could play a pivotal role in revolutionary cancer care, which could significantly alter the prognosis of individuals with genetically defined cancers, improving both the quality and the duration of their lives. It’s clear that the success of Aprea Therapeutics could be integral to ushering new hope for cancer patients around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aprea Therapeutics (Nasdaq: APRE) reported its financial results for the second quarter ended June 30, 2026, highlighting $41.2 million in cash and cash equivalents. The company is accelerating enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor APR-1051, with plans to advance it for uterine serous carcinoma and platinum-resistant ovarian cancer, and in combination regimens for HPV-positive head and neck cancer and colorectal cancer. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051.
Aprea Therapeutics (APRE) reported a net loss of $3.6 million, or $0.07 per share, for the second quarter of 2026. The company ended the quarter with $41.2 million in cash, expected to fund operations into Q1 2028, and plans to release further clinical data on its WEE1 inhibitor APR-1051 in Q4 2026. Institutional investors showed mixed activity, with some adding shares and others divesting.
Aprea Therapeutics Inc is projected to report a loss of 23 cents per share. This information is part of an earnings preview, indicating financial analysts' expectations for the company's upcoming earnings report. The full article is available to TradingView subscribers.